Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)

£29,383.99

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) was approved by the EMA in April 2019 under the trade name Ondexxya (andexanet alfa). It is available to order as well. See Ondexxya (andexanet alfa).

DISEASE INDICATIONS

Thromboembolism

MANUFACTURER

Alexion Pharmaceuticals

USAGE

Intravenous

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
ANDEXXA (COAGULATION FACTOR XA (RECOMBINANT), INACTIVATED-ZHZO) Package

4 vials of 100 mg, 4 vials of 200 mg

Reviews

There are no reviews yet.

Be the first to review “Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)”

Your email address will not be published. Required fields are marked *

Shopping Cart